Some Products May Appear Restricted
To ensure a smooth and speedy checkout, please log in to your account. Some items may show as restricted simply because you're not logged in.
If you do not have an account, you can register using our registration webform (https://www.avantorsciences.com/us/en/login/register)
If you're still seeing restrictions after logging in, certain products—like chemicals or medical devices—require additional account verification steps to be able to place an order. Some items may additionally require a specific license or customer documentation; additional documentation will be requested for these items prior to shipment.
Specifications
- Antibody Type:Primary
- Antigen Symbol:VEGFR-2
- Clonality:Monoclonal
- Clone:EIC
- Conjugation:Unconjugated
- ELISA:Yes
- Flow Cytometry:Yes
- Isotype:IgG1
- Reactivity:Human
- Western Blot:Yes
- Size:100 µg
- Form:Solid
- Gene ID:P35968
- Antigen Synonyms:Vascular Endothelial Growth Factor Receptor-2|KDR|FLK-1
- Storage Temperature:–20 °C
- Shipping Temperature:-20° C
- Immunogen:Recombinant human soluble extracellular VEGFR-2.
- Cat. No.:102978-612
- Supplier no.:AG20T0108C100
Specifications
About this item
Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not been previously described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein, designated endogenous soluble VEGFR-2 (esVEGFR-2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function. Tissue-specific loss of esKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of esKDR inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels; modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema.
Type: Primary
Antigen: VEGFR-2
Clonality: Monoclonal
Clone: EIC
Conjugation: Unconjugated
Epitope:
Host:
Isotype: Mouse IgG1
Reactivity: Human